

# Cost-Effectiveness of Screening Older Adult Smokers for Lung Cancer with an Autoantibody Test (AABT)

Peter Boyle<sup>1</sup>, Derek Weycker<sup>2</sup>, Anne Khuu<sup>2</sup>, James R. Jett<sup>3</sup>, Frank C. Detterbeck<sup>4</sup>, Timothy C. Kennedy<sup>5</sup>, Daniel L. Miller<sup>6</sup>, Herbert Fritsche<sup>7</sup>, William C. Wood<sup>6</sup>, Geoffrey Hamilton-Fairley<sup>8</sup>, John F. R. Robertson<sup>9</sup>, John Edelsberg<sup>2</sup>

<sup>1</sup>International Prevention Research Institute (iPRI), Lyon, France; <sup>2</sup>Policy Analysis Inc. (PAI), Brookline, MA; <sup>3</sup>Mayo Clinic, Rochester, MN; <sup>4</sup>Yale University, New Haven, CT; <sup>5</sup>University of Colorado Cancer, Denver, CO; <sup>6</sup>Emory University, Atlanta, GA; <sup>7</sup>MD Anderson Cancer Center, Houston, TX; <sup>8</sup>Oncimmune Ltd., Nottingham, England; <sup>9</sup>The University of Nottingham, Nottingham, England

## BACKGROUND

- Lung cancer (LC) is most common cause of cancer death in US, in part because it typically is not diagnosed until advanced stages
- Trials suggest screening with computed tomography (CT) may yield favorable shift in LC stage at diagnosis, although a survival benefit has not been convincingly demonstrated
- AABT—*Early*CDT-Lung (Oncimmune Ltd)—to aid in LC detection recently developed:
  - AABT comprises 6 tumor-related antigens produced by LC cells and detectable several years before tumor large enough to appear on CT
- While less sensitive than CT, AABT can detect smaller, less-advanced cancers; it also has greater specificity than CT
- Patients who are positive on both AABT and CT are 3-4 times more likely to have LC; aggressive evaluation and treatment may yield tangible (eg, survival) benefits

## STUDY OBJECTIVE

- To estimate cost-effectiveness of screening older adult smokers for LC with AABT, using techniques of decision-analytic modeling

## STUDY METHODS Model Description

- Model depicts clinical and economic consequences of alternative strategies for LC screening in cohort of 100,000 screening-naïve older adult smokers
- Model considers a single “prevalence-round” screening exam
- Strategies include:
  - AABT followed by CT if positive (AABT→CT)
  - AABT plus CT (AABT+CT)
  - CT alone
  - No Screening
- Patients assumed to be 60 years of age and at high-risk of having previously undetected LC due to current smoking:
  - NSCLC stratified based on nature of disease—aggressive vs. indolent; all SCLC considered to be aggressive
- Patients classified into one of four groups—true-positive, true-negative, false-positive, false-negative—based on LC+ vs LC- and screening+ vs screening-
- True-positives undergo further diagnostic evaluation followed by LC treatment:
  - Diagnostic tests employed, and their scheduling, depend on whether AABT and/or CT are positive, and nodule size
  - Detection of aggressive NSCLC/SCLC by CT screening yields earlier stage and smaller tumor (NSCLC stage 1), which confer survival benefits (vs no screening):
  - LC detected with AABT assumed, on average, to be smaller and less advanced, which results in stage, size, and survival benefits
- Detection of indolent NSCLC by screening (“overdiagnosis bias”) generates additional costs but confers no survival benefit

## Model Description (Cont.)

- True-negatives undergo no further diagnostic evaluation
- False-positives undergo additional evaluation that ultimately rules out diagnosis
- False-negatives with aggressive NSCLC/SCLC are correctly diagnosed, on average, 12 months following screening and subsequently undergo LC treatment:
  - Cancer assumed to have same size/stage as that detected in clinical practice, and thus to be more advanced than that for true-positives
  - Vast majority of patients with false-negative indolent NSCLC never diagnosed
- Costs include: initial screening (all patients); follow-up diagnostic evaluation (true-positives and false-positives); LC treatment (true-positives and false-negatives)
- Study perspective is US healthcare system ; future benefits and costs (2008US\$) discounted at 3% per year

## Model Estimation

- LC prevalence estimated assuming a three-year “look-forward period”:
  - AABT+ could result from tumor detectable by CT at time of screening or from one so small it would not be detectable by CT for up to three years
- CT sensitivity/specificity calculated from “prevalence-screen” perspective based on results of Mayo Clinic study<sup>1-3</sup>; for AABT, estimates based on published data<sup>4,5</sup>

Table 1. Estimated values of selected model parameters

Model Parameter	Value		Reference
	NSCLC	SCLC	
<b>Disease Characteristics</b>			
Prevalence of Lung Cancer, %	4.10%	0.72%	1-3, 6, 7
Type of Lung Cancer, %	85%	15%	7
<b>Screening Test Characteristics</b>			
CT			
Sensitivity	47%	47%	
Specificity	49%	49%	
AABT			
Sensitivity	40%	40%	4, 5
Specificity	93%	93%	
<b>Stage Shift vs No Screening, %</b>			
CT	50%	25%	8 (NSCLC), Expert Opinion (SCLC)
AABT→CT	80%	40%	Expert Opinion
AABT+CT	62.6%	31.3%	Derived
<b>Size Shift (Stage 1) vs No Screening, mm</b>			
CT	16.0	---	2
AABT→CT	18.0	---	Expert Opinion
AABT+CT	17.2	---	Derived
<b>Overdiagnosis Bias, %</b>			
CT	27%	---	9
<b>Costs</b>			
Initial Screen			
CT	\$301	\$301	10
AABT	\$300	\$300	Assumed
<b>LC Treatment</b>			
11			
Initial Year (Stage 1 - 4)	\$35,871 - \$50,346	\$50,346	
Continuing Years (Annual)	\$4,576	\$4,576	
Last Year of Life (Stage 1 - 4)	\$46,295 - \$78,623	\$78,623	

\*Stage shift defined as reclassification of given percentage of stage III and IV tumors to stages I and II in same proportion as these stages occur absent screening

## Analyses

- Cost-effectiveness calculated as ratio of difference in expected costs to difference in expected quality-adjusted life-years (QALYs) between:
  - AABT→CT vs No Screening and CT alone, respectively
  - AABT+CT vs No Screening and CT alone, respectively
  - CT vs No Screening

## RESULTS Outcomes

- Of 3,720 cases of aggressive NSCLC/SCLC, 1,488 (true-positives) would be detected with AABT→CT, 2,537 with AABT+CT, and 1,748 with CT alone; false-positives would total 6,662 (AABT→CT), 51,802 (AABT+CT), and 48,538 (CT alone)

Table 2. Classification from screening for lung cancer in a hypothetical population of 100,000 older adult smokers

	No Screening	CT	AABT→CT	AABT+CT
True Negatives	96,123	46,634	88,510	43,370
False Positives	---	48,538	6,662	51,802
True Positives	---	2,269	1,931	3,293
NSCLC	---	1,929	1,641	2,799
Aggressive	---	1,408	1,198	2,043
Indolent	---	521	443	756
SCLC	---	340	290	494
False Negatives	3,877	2,559	2,897	1,535
NSCLC	3,153	2,175	2,463	1,305
Aggressive	2,996	1,588	1,798	953
Indolent	157	587	665	352
Detected	157	0	0	0
Undetected	0	587	665	352
SCLC	724	384	434	230

- Compared with no screening, screening would increase costs by \$403 (AABT→CT), \$1198 (AABT+CT), and \$791 (CT alone) per patient, and yield an additional 0.04 (AABT→CT), 0.06 (AABT+CT), and 0.03 (CT alone) QALYs per patient


Table 3. Outcomes from screening for lung cancer in a hypothetical population of 100,000 older adult smokers\*

	No Screening	CT	AABT→CT	AABT+CT
Life-Years	1,360	1,365	1,366	1,368
Quality-Adjusted Life-Years	1,145	1,148	1,149	1,151
Cost	\$316,356	\$395,497	\$356,700	\$436,141
Screening	\$0	\$30,051	\$32,582	\$60,051
Diagnostic Follow-up	\$13,437	\$52,694	\$20,845	\$59,183
Treatment	\$302,920	\$312,752	\$303,272	\$316,907

\*Discounted values, in 000s

## RESULTS (CONT.) Cost-Effectiveness

Figure. Cost-effectiveness of screening for lung cancer with AABT→CT and AABT+CT versus no screening and versus screening with CT alone, respectively



\*Less costly, more effective

## Sensitivity Analyses

Table 4. Sensitivity analyses on cost per QALY gained

Base-case	AABT→CT vs		AABT+CT vs	
	No Screening	CT	No Screening	CT
Base-case	\$9,549	Dominant	\$21,488	\$16,213
Prevalence				
Age 50 (1.37%)	\$24,134	Dominant	\$49,453	\$36,782
Age 70 (10.11%)	\$7,040	Dominant	\$18,308	\$14,036
Cost of AABT screening				
\$0	\$2,448	Dominant	\$16,106	\$4,246
\$100	\$4,815	Dominant	\$17,900	\$8,235
\$200	\$7,182	Dominant	\$19,694	\$12,224
\$500	\$14,283	Dominant	\$25,075	\$24,191
Sensitivity - AABT				
20%	\$16,835	\$46,692 (CT)	\$24,755	\$22,796
30%	\$11,987	Dominant	\$22,992	\$18,829
60%	\$7,074	Dominant	\$19,088	\$13,004
Specificity - AABT				
80%	\$14,902	Dominant	\$23,856	\$21,479
95%	\$8,726	Dominant	\$21,123	\$15,403
Stage Shift - AABT→CT				
NSCLC 65%, SCLC 40%	\$12,411	---	---	---
NSCLC 50%, SCLC 40%	\$16,803	---	---	---
NSCLC 25%, SCLC 40%	\$33,365	---	---	---
NSCLC 80%, SCLC 0%	\$10,564	---	---	---
Stage Shift - AABT→CT vs CT				
NSCLC 65% vs 50%, SCLC 40% vs 25%	---	Dominant	---	---
NSCLC 50% vs 50%, SCLC 40% vs 25%	---	\$99,599 (CT)	---	---
NSCLC 25% vs 25%, SCLC 40% vs 25%	---	\$261,520 (CT)	---	---
NSCLC 80% vs 50%, SCLC 0% vs 0%	---	Dominant	---	---
Stage Shift - AABT+CT				
NSCLC 50%, SCLC 31.3%	---	---	\$27,407	---
NSCLC 25%, SCLC 31.3%	---	---	\$53,744	---
Stage Shift - AABT+CT vs CT				
NSCLC 50% vs 50%, SCLC 31.3% vs 25%	---	---	---	\$30,811
NSCLC 25% vs 25%, SCLC 31.3% vs 25%	---	---	---	\$58,581

## CONCLUSION AND CLINICAL IMPLICATION

- Screening older adult smokers for LC using AABT, in conjunction with CT, is likely to be cost-effective by current standards versus CT screening or no screening
- Use of AABT in early detection of lung cancer is supported by clinical as well as economic evidence

## REFERENCES

- Swensen, *Am J Respir Crit Care Med* 2002;165:508-13
- Swensen, *Radiology* 2003;226:756-61
- Swensen, *Radiology* 2005;235:259-65
- Boyle, *Ann Oncol* 2010;22:383-9
- Murray, *Ann Oncol* 2010;21:1687-93
- SEER Cancer Statistics Review 1975-2006, NCI website
- Fry, *Cancer* 1996;77:1947-55
- Mahadevia, *JAMA* 2003;289:313-22
- Linell, *Radiology* 2007;242:555-62
- RBRVS 2008; Chicago, Ill: American Medical Association
- Yabroff, *J Natl Cancer Inst* 2008;100:630-41